Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
Who can join
Ages 30 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * asthma- copd overlap * emphysema in smokers with smoking history \> 15 pack years * COPD/ bronchitis and bronchiectasis in smokers with smoking history * \>15 pack years Exclusion Criteria:other pulmonary or systemic diagnosis * non smokers * any other pulmonary diagnosis * pulmonary fibrosis
About the study
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).
What is being tested
- As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap (other)
Sponsor: Gelb, Arthur F., M.D. · Participants: 60 · Started: Jan 1, 2017
Contact the study team
- Arthur F Gelb, MD · Phone: 562-633-2204
- Christine Fraser · Phone: 562-633-2204
Official record on ClinicalTrials.gov — NCT03263130
Locations in the U.S.
| California | Arthur F Gelb MD, Lakewood Arthur F Gelb MD, Lakewood |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.